Evidence map›Paper›PMID 42432709›Full record

ReviewJournal of nanobiotechnology2026

Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.

Xin Ye, Yunfeng Tao, Yu Min, Li Yang, Wenlin Wu, Zheran Liu, Zhigong Wei, Xingchen Peng

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin Ye *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, Sichuan, China.
Yunfeng Tao *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Yu Min *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Li YangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Wenlin WuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Zheran LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. zeno.liu@outlook.com.
Zhigong WeiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. weizg10@hotmail.com.
Xingchen PengDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. pxx2014@163.com.ORCID http://orcid.org/0000-0001-7042-718X

Funding

1.3.5 project for disciplines of excellence from West China Hospital of Sichuan University ZYYC23006Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, the Institutional Joint Innovation Fund from Sichuan University and Nuclear Power Institute of China 1-KJ-FWHT-WU-20240150Health Research Project of Chengdu Eastern New Area Management Committee 202304International Science and Technology Cooperation Program of Chengdu Science and Technology Bureau 2024-YF06-00011-HZ and 2022-GH03-00004-HZNational Natural Sciences Foundation of China 82473434Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0503000, 2023ZD0503004Regional Innovation and Development Joint Fund Key Project of the National Natural Science Foundation of China U24A20735Science and Technology Project of Sichuan Provincial Health Commission JH2023082Sichuan Science and Technology Program 2025YFHZ0087
6 · The paper itself

Abstract

Radiotherapy remains a cornerstone in the clinical management of malignancies, leveraging DNA damage and oxidative stress to eradicate tumor cells. Nonetheless, the emergence of intrinsic and acquired radioresistance significantly compromises its therapeutic efficacy. While nanomedicine has substantially advanced radiosensitization strategies, the existing literature has largely focused on physical dose enhancement or conventional apoptosis, and the systematic reprogramming of diverse cell death modes beyond conventional apoptosis in the radiotherapy context has received less systematic attention. The present review provides a cross‑pathway synthesis of how engineered nanomaterials redirect tumor cell fate beyond apoptosis to achieve next‑generation radiosensitization, while also identifying the specific limitations and knowledge gaps that currently impede progress in this rapidly evolving field. We first delineate the hierarchical sensitization mechanisms, beginning with physical energy deposition via high-Z elements, followed by chemical amplification of reactive oxygen species through nanozyme catalysis, and biological intervention in the "6R" principles of radiobiology. Crucially, we evaluate the potential capacity of advanced nanomaterials to bypass conventional apoptotic resistance by triggering ferroptosis, pyroptosis, cuproptosis, disulfidptosis, and other emerging programmed death pathways, with a focus on the current evidence base and remaining preclinical and translational challenges. Beyond localized cytotoxicity, we highlight the mechanistic potential of nanomedicine to induce immunogenic cell death and activate the cGAS-STING pathway, suggesting a possible framework for transforming RT into an "in situ vaccine" that could reshape the immunosuppressive TME. Furthermore, we discuss the clinical translation of landmark nano-radiosensitizers, such as NBTXR3 and AGuIX, while critically addressing fundamental bottlenecks in targeting efficiency, biodistribution, and biosafety. By synthesizing current trends and future perspectives, this review contributes a strategic roadmap for advancing the design of next-generation, intelligent nanoplatforms toward more precise and systemic radiosensitization.

Indexed as

NanomedicineNeoplasmsRadiation-Sensitizing AgentsAnimalsApoptosisCell DeathCuproptosisDisulfidptosisFerroptosisHumansNanostructuresReactive Oxygen SpeciesRadiation-Sensitizing AgentsReactive Oxygen SpeciesCell deathNanomedicineRadiosensitizationRadiotherapyTumor microenvironment

Identifiers

PMID42432709
PMCPMC13637250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.